Carmen Remuñán López

Dr. Carmen Remuñán López

Nanobiofar Group (GI-1643), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Universidade de Santiago de Compostela-Campus Vida, 15782 Santiago de Compostela, Spain
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 1997 in Journal of Applied Polymer Science
Verified
Journal Article
Closed access
PDF file
PCP. Calvo
P. Calvo
CLCarmen Remuñán López
Carmen Remuñán López
JVJ. L. Vila-Jato
J. L. Vila-Jato
MAM. J. Alonso
M. J. Alonso

1 October 1997 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
PCPilar Calvo
Pilar Calvo
CLCarmen Remuñán López
Carmen Remuñán López
JVJose Luis Vila-Jato
Jose Luis Vila-Jato
MAMaria Jose Alonso
Maria Jose Alonso

1 October 1999 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
RFRocío Fernández‐Urrusuno
Rocío Fernández‐Urrusuno
PCPilar Calvo
Pilar Calvo
CLCarmen Remuñán López
Carmen Remuñán López
JVJose Luis Vila-Jato
Jose Luis Vila-Jato
MAMaria Jose Alonso
Maria Jose Alonso

1 July 2005 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
AGAna Grenha
Ana Grenha
BSBegoña Seijo
Begoña Seijo
CLCarmen Remuñán López
Carmen Remuñán López

17 September 2012 in Journal of Functional Biomaterials
Verified
Journal Article
Open access
PDF file
SRSusana Rodrigues
Susana Rodrigues
MDMarita Dionísio
Marita Dionísio
CLCarmen Remuñán López
Carmen Remuñán López
AGAna Grenha
Ana Grenha
Chitosan is one of the most used polysaccharides in the design of drug delivery strategies for administration of either biomacromolecules or low molecular weight drugs. For these purposes, it is frequently used as matrix forming material in both nano and micron-sized particles. In addition to its interesting physicochemical and biopharmaceutical properties, which include high mucoadhesion and a great capacity to produce drug delivery systems, ensuring the biocompatibility of the drug delivery vehicles is a highly relevant issue. Nevertheless, this subject is not addressed as frequently as desired and even though the application of chitosan carriers has been widely explored, the demonstration of systems biocompatibility is still in its infancy. In this review, addressing the biocompatibility of chitosan carriers with application in drug delivery is discussed and the methods used in vitro and in vivo, exploring the effect of different variables, are described. We further provide a discussion on the pros and cons of used methodologies, as well as on the difficulties arising from the absence of standardization of procedures.

1 March 1998 in Journal of Controlled Release
Verified
Journal Article
Closed access
MLM.L Lorenzo-Lamosa
M.L Lorenzo-Lamosa
CLCarmen Remuñán López
Carmen Remuñán López
JVJ.L Vila-Jato
J.L Vila-Jato
MAMaria Jose Alonso
Maria Jose Alonso